References
- EHA Infectious Disease Scientific Working Group, Hirsch HH, von Lilienfeld-toal M, Vehreschild JJ, Cornely O, et al. Frequently asked questions regarding SARS-CoV-2 in cancer patients-recommendations for clinicians caring for patients with malignant diseases. Leukemia. 2020 Jun;34(6):1487–1494. .
- European hematology association - COVID-19 recommendations. [Cited 2020 Sep 03]. Available from: https://ehaweb.org/topics-in-focus/covid-19/covid-19-recommendations/recommendations-for-specific-hematologic-malignancies/.
- Ellsworth GB, Glesby MJ, Gulick RM. The uncertain role of corticosteroids in the treatment of COVID-19. JAMA Intern Med. 2020 August 03. DOI:10.1001/jamainternmed.2020.2444.
- Cao Y, Wei J, Zou L, et al. Ruxolitinib in treatment of severe coronavirus disease 2019 (COVID-19): A multicenter, single-blind, randomized controlled trial. J Allergy Clin Immunol. 2020 Jul;146(1):137–146.e3. .
- Pavord S, Thachil J, Hunt BJ, et al. Practical guidance for the management of adults with immune thrombocytopenia during the COVID-19 pandemic. Br J Haematol. 2020 Jun;189(6):1038–1043. .
- ASH Covid-19 resources. [Cited 2020 Sep 03]. Available from: https://www.hematology.org/covid–19
- Passamonti F, Cattaneo C, Arcaini L, et al. Clinical characteristics and risk factors associated with COVID-19 severity in patients with haematological malignancies in Italy: a retrospective, multicentre, cohort study. Lancet Haematol. 2020 Oct;7(10):e737–e745. .
- Treon SP, Castillo JJ, Skarbnik AP, et al. The BTK inhibitor ibrutinib may protect against pulmonary injury in COVID-19-infected patients. Blood. 2020;135(21):1912–1915. .
- Nickel RS, Margulies S, Frazer B, et al. Combination dose-escalated hydroxyurea and transfusion: an approach to conserve blood during the COVID-19 pandemic. Blood. 2020;135(25):2320–2322. .
- Taher AT, Bou-Fakhredin R, Kreidieh F, et al. Care of patients with hemoglobin disorders during the COVID-19 pandemic: an overview of recommendations. Am J Hematol. 2020;95(8):E208–E210. .
- Dalamaga M, Karampela I, Mantzoros CS. Commentary: could iron chelators prove to be useful as an adjunct to COVID-19 treatment regimens? Metabolism. 2020;108:154260.
- Sahu KK, Siddiqui AD, Cerny J. Managing sickle cell patients with COVID-19 infection: the need to pool our collective experience. Br J Haematol. 2020;190(2):e86–e89.
- Sahu KK, Raturi M, Siddiqui AD, et al. “Because every drop counts”: blood donation during the COVID-19 pandemic. Transfus Clin Biol. 2020;27(3):105–108.
- Nawar T, Morjaria S, Kaltsas A, et al. Granulocyte‐colony stimulating factor in COVID‐19: is it stimulating more than just the bone marrow? Am J Hematol. 2020;95:E210–E213.
- COVID‐19 (coronavirus disease 2019) pandemic caused by SARS‐CoV‐2: practical recommendations for people with hemophilia. [Cited 2020 Sep 03]. Available from: https://news.wfh.org/covid‐19‐coronavirus‐disease‐2019‐pandemic‐caused‐by‐sars‐cov‐2‐practical‐recommendations‐for‐hemophilia‐patients/
- Hardy M, Lecompte T, Douxfils J, et al. Management of the thrombotic risk associated with COVID-19: guidance for the hemostasis laboratory. Thromb J. 2020;18:17.
- Wang X, Sahu KK, Cerny J. Coagulopathy, endothelial dysfunction, thrombotic microangiopathy and complement activation: potential role of complement system inhibition in COVID-19. J Thromb Thrombolysis. 2020 Oct 15:1–6.